Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Antibody shows promise in eosinophilic gastritis/duodenitis

Publish date:: October 28, 2020

Key clinical point: Antibody could be safer than steroids for long-term treatment.

Major finding: Eosinophils dropped by 86% in the treatment group and increased by 9% in controls.

Study details: A phase 2, randomized, controlled trial (n = 65).

Disclosures: The study was funded by Alkalos. Dr. Semrad has no relevant financial disclosures.

Citation:

Dellon ES et al. N Engl J Med. 2020 Oct 22. doi: 10.1056/NEJMoa2012047

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

IBD patients prefer vedolizumab over anti-TNF drugs,

During pandemic, many gastroenterologists report low resilience, insomnia,